Table 4.

Recommendations for patient on pre-existing thrombotic therapy from the global COVID-19 thrombosis Collaborative group^{37 38 41}

Population	Recommendation
Patients with mild COVID-19 (outpatient)38	Mild COVID-19 is not a known risk of anti-thrombotic agents; continue taking antithrombotic agents as recommended for patients on antithrombotics for prior known thrombotic disease
Patients with moderate to severe COVID-19 with suspected or confirmed DIC without overt bleeding on chronic therapeutic anticoagulation38	Weigh anticoagulation indication against bleeding risk, consider dose adjustment or discontinuation Majority of the authors recommend reducing anticoagulation intensity barring exceedingly high thrombosis risk
Patients with moderate to severe COVID-19 without overt bleeding on dual antiplatelet therapy38	Individualised decisions for antiplatelet therapy In general, consider continuing dual antiplatelet therapy for platelet counts >50 000; reduce to single antiplatelet for platelet count 25 000–50,000; discontinue antiplatelets if platelet count <25 000
Patients with moderate to severe COVID-19 on existing anticoagulation for other diseases, for example, atrial fibrillation	Consider changes to therapeutic low-molecular-weight heparins while an inpatient for safer monitoring profile and less interactions with other drugs37 If breakthrough VTE occurs while on oral anticoagulants recommend changing over to low molecular weight heparins37 41 If significant renal dysfunction present, consider unfractionated heparin

VTE, venous thromboembolism.